Rockefeller Capital Management L.P. Raises Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Rockefeller Capital Management L.P. grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 16.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 266,633 shares of the biotechnology company’s stock after buying an additional 37,805 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.14% of BioMarin Pharmaceutical worth $18,742,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BMRN. Tidal Investments LLC grew its stake in shares of BioMarin Pharmaceutical by 65.5% in the 1st quarter. Tidal Investments LLC now owns 17,447 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 6,906 shares in the last quarter. Quent Capital LLC boosted its stake in shares of BioMarin Pharmaceutical by 58.9% during the 2nd quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 145 shares during the period. CWM LLC boosted its stake in shares of BioMarin Pharmaceutical by 68.5% during the 2nd quarter. CWM LLC now owns 2,398 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 975 shares during the period. Inspirion Wealth Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical by 2.3% during the 2nd quarter. Inspirion Wealth Advisors LLC now owns 13,458 shares of the biotechnology company’s stock worth $1,108,000 after purchasing an additional 304 shares during the period. Finally, Securian Asset Management Inc. purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $1,247,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BMRN has been the subject of a number of recent analyst reports. Citigroup dropped their price target on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. StockNews.com upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. decreased their price objective on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating for the company in a report on Wednesday, October 30th. TD Cowen decreased their price objective on shares of BioMarin Pharmaceutical from $125.00 to $120.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Finally, Wells Fargo & Company decreased their price objective on shares of BioMarin Pharmaceutical from $115.00 to $90.00 and set an “overweight” rating for the company in a report on Tuesday, September 17th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $94.20.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the sale, the executive vice president now owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.85% of the stock is owned by insiders.

BioMarin Pharmaceutical Trading Up 0.9 %

NASDAQ BMRN opened at $66.03 on Monday. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. The firm has a market cap of $12.58 billion, a PE ratio of 39.54, a price-to-earnings-growth ratio of 0.65 and a beta of 0.31. The company has a 50 day moving average price of $67.72 and a 200 day moving average price of $77.88. BioMarin Pharmaceutical Inc. has a 52 week low of $61.15 and a 52 week high of $99.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.23). The firm had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The company’s revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.26 EPS. As a group, sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 2.49 EPS for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.